Anixa Biosciences, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.24%334.050.0%$4535.66m
NVAXNovavax, Inc. -0.93%164.7079.4%$740.89m
BNTXBioNTech SE 1.34%264.580.0%$714.22m
AMGNAmgen, Inc. 1.37%205.911.4%$545.61m
REGNRegeneron Pharmaceuticals, Inc. 1.88%553.682.7%$427.43m
SNSSSunesis Pharmaceuticals, Inc. -2.48%6.110.7%$427.11m
GILDGilead Sciences, Inc. 1.59%66.951.0%$414.33m
CCXIChemoCentryx, Inc. 5.58%34.242.9%$406.70m
ILMNIllumina, Inc. 0.07%410.833.3%$374.94m
XLRNAcceleron Pharma, Inc. 0.27%173.465.3%$363.41m
VRTXVertex Pharmaceuticals, Inc. 1.59%183.681.9%$262.38m
BIIBBiogen, Inc. 0.04%269.851.7%$233.76m
OCGNOcugen, Inc. 2.79%8.490.0%$183.51m
XENEXenon Pharmaceuticals, Inc. -0.81%30.470.4%$170.35m
CRSPCRISPR Therapeutics AG 4.56%100.600.6%$161.25m

Company Profile

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.